Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

5125 - Meta-analysis Of The Effect Of Rituximab İn The Treatment Of Primary Central Nervous System Lymphoma

Date

09 Sep 2017

Session

CNS tumours

Presenters

Sinan Yavuz

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

S. Yavuz1, M. Yildirim2, G. Yazıcı3, V. Kaya4, S. Paydas5

Author affiliations

  • 1 Medical Oncology, Acıbadem University, 01735 - Adana/TR
  • 2 İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR
  • 3 Department Of Radiation Oncology, Hacettepe University School of Medicine, Ankara/TR
  • 4 Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 5 Medical Oncology, Cukurova University, 01330 - Adana/TR
More

Resources

Abstract 5125

Background

Primary central nervous system lymphoma (PCNSL) is a rare subtype of agressive non-hodgkin lymphoma (NHL), and is most commonly of B cell phenotype. The standard treatment is not well established but high dose methotraxate is the most commonly used regimen. Intravenous rituximab (iv Rtx) treatment is integrated into the protocols for systemic B cell lymphomas. However there are mixed results with the use of Rtx. The aim of this meta-analysis is to investigate the role of iv Rtx in the treatment of PCNSL.

Methods

PubMed and EBSCOhost databases are searched for rituximab, primary central nervous lymphoma, rituximab, survival. Browsing databases was done in English.

Results

580 patients were included to meta-analysis. Pooled hazard ratio showed that overall survival is correlated with iv Rtx (HR, 0,498; 95% CI, 0,366 - 0,678; p:

Conclusions

In this meta-analysis, we showed that the addition of iv Rtx as part of a treatment protocol for PCNSL has a positive impact on survival.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.